[Complement activation and inflammation]
- PMID: 16913666
[Complement activation and inflammation]
Abstract
The complement system not only plays an important role in the defense system, but also contributes to the amplification of inflammation if activated in excess or inappropriately controlled. Complement activation through one of three pathways is tightly controlled by various regulators of complement activation (RCA) which are constitutively expressed on various cells in order to restrict excessive activation. Complement activation may generate polypeptides, so-called anaphylatoxins, and membrane attack complex (MAC) with large molecular mass. Anaphylatoxins (C3a, C4a, and C5a) produced by activation of the complement is considered to bridge innate and acquired immunity. Considering that C5a is more potent than C3a, but the serum concentration of C3 is 10 times higher than that of C5, the overall effects of C3a may be comparative with those of C5a. Since both anaphylatoxins are considered to exert their actions through rhodopsin-typed receptors, their receptor antagonists are targets for the discovery of anti-inflammatory and immune-modulating drugs. Complement activation may be related to the pathophysiology of various refractory disorders including ARDS, asthma, septic syndrome, SLE, rheumatoid arthritis, ischemia-reperfusion injury, and psoriasis etc. Pharmacological manipulation of the complement system may consist of various strategies including (1) inhibitors of complement activation at various levels, (2) receptor antagonists of anaphylatoxins, C3a and C5a, and (3) inhibitors of C5a including monoclonal antibody. Candidate agents concerning the above-mentioned manipulations have being produced and some are now in progress toward clinical trials in patients with certain diseases.
Similar articles
-
A novel interpretation of immune redundancy and duality in reperfusion injury with important implications for intervention in ischaemic disease.Med Hypotheses. 2007;68(6):1363-70. doi: 10.1016/j.mehy.2006.10.044. Epub 2006 Dec 13. Med Hypotheses. 2007. PMID: 17169498
-
Complement mediated inhibition of immune precipitation and solubilization generate different concentrations of complement anaphylatoxins (C4a, C3a, C5a).Clin Exp Immunol. 1986 May;64(2):407-14. Clin Exp Immunol. 1986. PMID: 3488858 Free PMC article.
-
Accentuated complement activation in patient plasma during the adult respiratory distress syndrome: a potential mechanism for pulmonary inflammation.Heart Lung. 1989 Jan;18(1):71-84. Heart Lung. 1989. PMID: 2783581
-
The anaphylatoxins bridge innate and adaptive immune responses in allergic asthma.Mol Immunol. 2004 Jun;41(2-3):123-31. doi: 10.1016/j.molimm.2004.03.019. Mol Immunol. 2004. PMID: 15159057 Review.
-
Evolution of anaphylatoxins, their diversity and novel roles in innate immunity: insights from the study of fish complement.Vet Immunol Immunopathol. 2005 Oct 18;108(1-2):77-89. doi: 10.1016/j.vetimm.2005.07.009. Vet Immunol Immunopathol. 2005. PMID: 16112742 Review.
Cited by
-
Pretreatment with atorvastatin ameliorates cobra venom factor-induced acute lung inflammation in mice.BMC Pulm Med. 2020 Oct 12;20(1):263. doi: 10.1186/s12890-020-01307-3. BMC Pulm Med. 2020. PMID: 33046059 Free PMC article.
-
Anticomplementary principles of a Chinese multiherb remedy for the treatment and prevention of SARS.J Ethnopharmacol. 2008 May 8;117(2):351-61. doi: 10.1016/j.jep.2008.02.012. Epub 2008 Feb 17. J Ethnopharmacol. 2008. PMID: 18400428 Free PMC article.
-
Complement and the alternative pathway play an important role in LPS/D-GalN-induced fulminant hepatic failure.PLoS One. 2011;6(11):e26838. doi: 10.1371/journal.pone.0026838. Epub 2011 Nov 1. PLoS One. 2011. PMID: 22069473 Free PMC article.
-
Complement inhibition alleviates paraquat-induced acute lung injury.Am J Respir Cell Mol Biol. 2011 Oct;45(4):834-42. doi: 10.1165/rcmb.2010-0444OC. Epub 2011 Mar 18. Am J Respir Cell Mol Biol. 2011. PMID: 21421909 Free PMC article.
-
Complement C1q expression in Erythema nodosum leprosum.PLoS Negl Trop Dis. 2018 Mar 2;12(3):e0006321. doi: 10.1371/journal.pntd.0006321. eCollection 2018 Mar. PLoS Negl Trop Dis. 2018. PMID: 29499046 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous